Tue, 7 April 2020
In this episode, we chat with Eris Tollkuci, PharmD, BCOP regarding what every non-onc healthcare provider should know about immune checkpoint inhibitors (specifically PD-1/PD-L1 inhibitors) in patients with cancer. |
Tue, 17 March 2020
In this episode, we summarize some of the most significant changes in the newest version of American Diabetes Association - 2020 Standards of Medical Care in Diabetes guidelines. |
Tue, 25 February 2020
In this episode, we review the pros, cons, and literature regarding the use of DOACs versus warfarin in obese patients with venous thromboembolism. |
Tue, 4 February 2020
In this episode, we provide an overview of lifestyle medicine, its six pillars, and how it plays a role in improving health outcomes. |
Tue, 14 January 2020
In this episode, we discuss clinical pearls and management related to chronic and acute hyperkalemia. |
Tue, 24 December 2019
In this episode, we discuss the important updates in the 2019 IDSA Community Acquired Pneumonia (CAP) guidelines with Dr. Christie Bertram, PharmD, an Infectious Diseases Clinical Pharmacist and Assistant Professor at Rosalind Franklin University’s College of Pharmacy. |
Tue, 3 December 2019
In this episode, we review the three oral P2Y12 inhibitors on the market (clopidogrel, prasugrel, ticagrelor) and discuss each agent’s clinical pearls, comparative effectiveness, and unique precautions. |
Tue, 12 November 2019
In this episode, we will discuss what is the latest and greatest from the GINA (Global INitiative for Asthma) 2019 guidelines, including new recommendations regarding rescue inhalers, tiotropium, and azithromycin for asthma. |
Tue, 22 October 2019
In this episode, we discuss the newly published DAPA-HF trial, which studied dapagliflozin (a drug for diabetes) among patients who had heart failure with reduced ejection fraction (HFrEF) many of which did NOT have a history of diabetes. |
Tue, 1 October 2019
In this episode, we provide an overview of chronic idiopathic constipation and discuss available treatment options with a particular focus on lubiprostone, linaclotide, plecanatide, and prucalopride. |